Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

FDA grants Breakthrough Therapy Designation for Xolair for food allergies [Seeking Alpha]

ROCHE HOLDING LTD S/ADR (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
Company Research Source: Seeking Alpha
Genentech, a member of the Roche Group ( OTCQX:RHHBY ), announces that the FDA has granted Breakthrough Therapy Designation for Xolair  (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application. Click to subscribe to real-time analytics on RHHBY Now read: Roche: Where Is The Dividend Growth ? » Subscribe for full text news in your inbox Show less Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RHHBY alerts
Opt-in for
RHHBY alerts

from News Quantified
Opt-in for
RHHBY alerts

from News Quantified